Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
8 search results for:

Merkel cell carcinoma 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 28-03-2017 | Merkel cell carcinoma | Drug approval | Article
    approvalsWatch

    Avelumab given accelerated approval for metastatic Merkel cell carcinoma

    medwireNews : The US FDA has given accelerated approval and orphan drug status for the use of avelumab in patients aged 12 years and older with metastatic Merkel cell carcinoma.

  2. 13-07-2022 | Immunotherapy | News | Article

    ICI therapy feasible in advanced cancer patients with kidney transplant using immunosuppression

    Their phase 1 study included 17 patients with incurable, locally advanced or metastatic tumors, namely cutaneous cell carcinoma (35%) or squamous cell carcinoma (18%) of the head and neck, cancers of the kidney (12%), liver (6%), lung (6%), or colon (6%), Merkel cell carcinoma (12%), or melanoma (6%) from three Australian hospitals.

    Author:
    Lynda Williams
    Published in:
    Lancet Oncol 2022; doi: 10.1016/S1470-2045(22)00368-0 Lancet Oncol 2022; doi: 10.1016/S1470-2045(22)00395-3
  3. 06-07-2020 | FDA | News | Article
    approvalsWatch

    Maintenance avelumab approved for advanced urothelial carcinoma after platinum chemotherapy

    Avelumab has previously been approved for the treatment of urothelial carcinoma that has progressed after platinum-based chemotherapy, as well as other indications including advanced renal cell carcinoma  in combination with axitinib, Merkel cell carcinoma , and lung cancer . 

    Author:
    Lynda Williams
  4. 25-09-2019 | EMA | News | Article
    approvalsWatch

    Avelumab indication extended in Europe to advanced RCC

    Avelumab has previously been granted approval in Europe for the treatment of metastatic Merkel cell carcinoma.

  5. 05-02-2019 | Immunotherapy | News | Article

    Immune-related AEs linked to improved outcome on anti-PD-1 therapy

    Patients who develop immune-related adverse events while receiving anti-programmed cell death protein 1 antibodies for advanced cancer have a substantially greater treatment response than those with no such events, say researchers.

    Published in:
    Eur J Cancer 2019; 109 : 21–27
  6. 06-04-2018 | Clinical trial | News | Article

    In other news

    Among 1738 patients with advanced solid tumors or previously treated metastatic Merkel cell carcinoma, grade 3 or worse treatment- and immune-related adverse events (AEs) occurred in a corresponding 10.2% and 2.2% of participants, and led to discontinuation in 6.2% and 2.0%, respectively.

  7. 17-08-2017 | EMA | Drug approval | Article
    approvalsWatch

    Multiple orphan medications get nod from EMA

    . --- The committee has recommended granting a marketing authorization to avelumab for the treatment of adults with metastatic Merkel cell carcinoma.

  8. 16-05-2017 | FDA | News | Article
    approvalsWatch

    Avelumab, pembrolizumab indications expanded

    The programmed death ligand 1 (PD-L1) inhibitor avelumab, recently given approval for metastatic Merkel cell carcinoma , may now be given to patients with urothelial carcinoma that has progressed during platinum-based chemotherapy or within a year of receiving a platinum-containing neoadjuvant or adjuvant regimen.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.